What Is in the Myopathy Literature?

This update begins with a discussion of treatable lipid storage myopathies associated with the use of sertraline and ranolazine. We then turn to monoclonal gammopathy-associated myopathies including a more recently identified disorder that is also treatment-responsive, monoclonal gammopathy-associated glycogen storage myopathy. Several reports on statins and muscle symptoms, toxic myopathy, and immune-mediated necrotizing myopathy follow. Other autoimmune myopathy topics are highlighted. Then, muscular dystrophies are covered with a focus on dystrophinopathies, limb-girdle muscular dystrophy, and facioscapulohumeral muscular dystrophy. Pompe disease follows with a focus on enzyme replacement therapy data. A short section on congenital myopathies precedes a review of reports on myotonic dystrophies and nondystrophic myotonias.